The latest price target for Aadi Bioscience (NASDAQ:AADI) was reported by Piper Sandler on August 27, 2024. The analyst firm set a price target for $1.75 expecting AADI to fall to within 12 months (a possible -41.08% downside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for Aadi Bioscience (NASDAQ:AADI) was provided by Piper Sandler, and Aadi Bioscience downgraded their neutral rating.

There is no last upgrade for Aadi Bioscience

The last downgrade for Aadi Bioscience Inc happened on August 27, 2024 when Piper Sandler changed their price target from $5 to $1.75 for Aadi Bioscience Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aadi Bioscience, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aadi Bioscience was filed on August 27, 2024 so you should expect the next rating to be made available sometime around August 27, 2025.

While ratings are subjective and will change, the latest Aadi Bioscience (AADI) rating was a downgraded with a price target of $5.00 to $1.75. The current price Aadi Bioscience (AADI) is trading at is $2.97, which is out of the analyst’s predicted range.